Cargando…
Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation
Retinopathy of prematurity (ROP) is a severe eye disease leading to blindness. Abnormal vessel formation is the pathological hallmark of neovascular ROP. In forming vessels, vascular endothelial growth factor (VEGF) is an important stimulator. The current anti-ROP therapy has focused on bevacizumab,...
Autores principales: | Hu, Wei-Hui, Zhang, Xiao-Yong, Leung, Ka-Wing, Duan, Ran, Dong, Ting-Xia (Tina), Qin, Qi-Wei, Tsim, Karl Wah-Keung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223486/ https://www.ncbi.nlm.nih.gov/pubmed/35742898 http://dx.doi.org/10.3390/ijms23126455 |
Ejemplares similares
-
Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer
por: Hu, Wei-Hui, et al.
Publicado: (2019) -
Treatment of retinopathy of prematurity (ROP)
por: Rajan, Renu Puthenvilayil, et al.
Publicado: (2018) -
Treatment of retinopathy of prematurity (ROP)
por: Rajan, Renu Puthenvilayil, et al.
Publicado: (2017) -
Survey on retinopathy of prematurity (ROP) in Italy
por: Borroni, Cesarina, et al.
Publicado: (2013) -
Genetic susceptibility to advanced retinopathy of prematurity (ROP)
por: Shastry, Barkur S
Publicado: (2010)